Exelixis (EXEL) Tops Q1 EPS by 2c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 5, 2020 4:05 PM EDT- Total Revenue of $226.9 Million, Cabozantinib Franchise Revenue of $193.9 Million -
- GAAP Diluted EPS of $0.15, Non-GAAP Diluted EPS of $0.19 -
- Conference Call and Webcast Today at 5:00 PM Eastern Daylight Time -
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Exelixis remained productive... More
